Another public biotech hops on the trial-win-to-stock-sale train, netting a nine-figure raise

Lei Lei Wu

News Reporter

After unveiling Phase II data that, according to Rezolute, “exceeded expectations” with a drug for congenital hyperinsulinism, the Silicon Valley-based biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another public biotech hops on the trial-win-to-stock-sale train, netting a nine-figure raise

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

An­oth­er pub­lic biotech hops on the tri­al-win-to-stock-sale train, net­ting a nine-fig­ure raise

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Another public biotech hops on the trial-win-to-stock-sale train, netting a nine-figure raise

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?